September is Alopecia Areata Awareness Month. Follow blue illuminations across the USA: #LightItUpBlue4AlopeciaAreata Learn More

Strategic Collaborations

We are collaborating with leading biopharmaceutical companies to apply our DCE Platform® to existing compounds with known therapeutic properties, including approved drugs, advanced clinical candidates or previously studied biologically active compounds. In these collaborative programs, incorporating deuterium may enable superior pharmacokinetic or metabolic properties and thereby offer the potential opportunity for best-in-class products with enhanced clinical safety, tolerability or efficacy.

Our clinical pipeline of drug candidates resulting from our DCE Platform includes novel drugs that are being developed with strategic collaborators, which include the following:

Under our license agreement, Avanir is developing AVP-786, which combines deuterium-substituted dextromethorphan and an ultra-low dose of quinidine. Avanir is conducting several Phase 2 and Phase 3 clinical trials to evaluate AVP-786 for the treatment of neurologic and psychiatric disorders.

Jazz Pharmaceuticals’ current once-nightly development efforts are focused on lower sodium compounds. The collaboration with Jazz Pharmaceuticals provides for the evaluation of deuterium as an option for a once nightly sodium oxybate product.

Under a license agreement, Cipla Technologies has worldwide rights to develop and commercial CTP-354. CTP-354 is a novel GABAA receptor subtype-selective modulator. Building on Concert’s initial preclinical and clinical evaluation, Cipla intends to develop CTP-354 for the treatment of spasticity and other CNS disorders.
Under a license agreement, Processa Pharmaceuticals has worldwide rights to develop and commercialize CTP-499, a deuterated analog of 1-(S)-5-hydroxyhexyl-3,7-dimethylxanthine, an active metabolite of pentoxifylline.

Asset Purchase Agreement

Under an asset purchase agreement, Vertex acquired worldwide development and commercialization rights to VX-561 (previously known as CTP-656) and other assets related to the treatment of cystic fibrosis. VX-561 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of cystic fibrosis. In 2017, Concert received a one-time cash payment of $160 million upon closing the asset purchase, with the potential for future milestones. In May 2021, Vertex purchased the potential future milestones under the companies’ asset purchase agreement relating to VX-561 for $32 million. Following receipt of the $32 million, no further milestone obligations remain.

For partnership inquiries, please contact:
BD@concertpharma.com

Back to Top